Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15867 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Sara Bettonte und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerla…. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Aims
Intramuscular cabotegravir/rilpivirine (IM CAB/RPV) are metabolized by UGT1A1/CYP3A4. Efavirenz induces both enzymes; therefore, switching from an efavirenz‐containing regimen to IM CAB/RPV could possibly result in suboptimal levels. Due to their long dosing interval, clinical studies with IM CAB/RPV are challenging. We used physiologically based pharmacokinetics (PBPK) modelling to simulate the switch from efavirenz to IM CAB/RPV.
Methods
First, we developed the drug models and verified the performance of the PBPK model to predict the pharmacokinetics of IM cabotegravir, IM rilpivirine and efavirenz by comparing the simulations against observed clinical data. Second, we verified the ability of the model to predict the effect of residual induction with observed data for the switch from efavirenz to dolutegravir or rilpivirine. Finally, we generated a cohort of 100 virtual individuals (20–50 years, 50% female, 18.5–30 kg/m 2 ) to simulate IM CAB/RPV concentrations after discontinuing efavirenz in extensive and slow metabolizers of efavirenz.
Results
IM CAB concentrations were predicted to decrease by 11% (95% confidence interval 7–15%), 13% (6–21%) and 8% (0–18%) at day 1, 7 and 14 after efavirenz discontinuation. CAB concentrations were predicted to remain above the minimal efficacy threshold (i.e., 664 ng/mL) throughout the switch period both in extensive and slow metabolizers of efavirenz. Similarly, IM RPV concentrations were modestly decreased with the lowest reduction being 10% (6–14%) on day 7 post last efavirenz dose.
Conclusion
Our simulations indicate that switching from an efavirenz‐containing regimen to IM CAB/RPV does not put at risk of having a time window with suboptimal drug levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
- Faculty of Medicine, University of Basel, Basel, Switzerland.
- Certara UK Limited, Sheffield, UK.
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.
ORCID-Profile: Sara Bettonte, Mattia Berton, Felix Stader, Manuel Battegay, Catia Marzolini
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Bettonte, S., Berton, M., Stader, F., Battegay, M., & Marzolini, C. (2023). Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15867
Vancouver
Bettonte S, Berton M, Stader F, Battegay M, Marzolini C. Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15867
BibTeX
@article{Bettonte2023,
author = {Bettonte, Sara and Berton, Mattia and Stader, Felix and Battegay, Manuel and Marzolini, Catia},
title = {Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15867}
}
EUVIMED